-
ENVIRONMENTAL IMPACT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS TREATMENTS ACROSS EUROPE: IMPLICATIONS FOR SUSTAINABLE PRESCRIPTION
Aug 11, 2026, 17:16 PM -
REAL-WORLD BOTTOM-UP COST-OF-ILLNESS ANALYSIS OF TYPE 2 DIABETES MELLITUS IN A SAUDI TERTIARY HOSPITAL
Aug 11, 2026, 17:16 PM -
IS THERE AN IMPLICIT COST-EFFECTIVENESS THRESHOLD IN FRANCE? EVIDENCE FROM CEESP ASSESSMENTS (2021-2026)
Aug 11, 2026, 17:16 PM -
MID- AND LONG-TERM NUMBER NEEDED TO TREAT FOR TILDRAKIZUMAB 200 MG IN MODERATE-TO-SEVERE PLAQUE PSORIASIS PATIENTS WITH BODY WEIGHT =90 KG
Aug 11, 2026, 17:16 PM -
AN INTEGRATED DISEASE CONCEPTUAL MODEL OF MULTIPLE SCLEROSIS (MS) FROM THE PATIENTS' PERSPECTIVE: A MULTINATIONAL QUALITATIVE STUDY
Aug 11, 2026, 17:16 PM -
ASSESSING THE POTENTIAL IMPACT OF U.S. MOST-FAVORED-NATION PRICING MODELS ON INNOVATIVE DRUG LAUNCHES IN CZECHIA
Aug 11, 2026, 17:16 PM -
EVALUATING THE TRANSPORTABILITY OF EFFICACY ESTIMATES IN RELAPSED/REFRACTORY MANTLE-CELL LYMPHOMA
Aug 11, 2026, 17:16 PM -
CAN ARTIFICIAL INTELLIGENCE RELIABLY PERFORM TITLE-ABSTRACT SCREENING FOR SYSTEMATIC LITERATURE REVIEWS?
Aug 11, 2026, 17:16 PM -
AXICABTAGENE CILOLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN BRAZIL: THE IMPACT OF CAR T-CELL THERAPY WAIT TIME AND TREATMENT SEQUENCING
Aug 11, 2026, 17:16 PM -
AI-ASSISTED RWE STUDY DESIGN AND REPORTING: QUANTIFYING TIME SAVINGS AND SCIENTIFIC EQUIVALENCE ACROSS PROTOCOL, SAP, CODE, AND REPORT AND MANUSCRIPT GENERATION
Aug 11, 2026, 17:16 PM -
FROM REAL-WORLD DATA TO DECISION-GRADE EVIDENCE IN RARE ONCOLOGY: LESSONS FROM CHRONIC MYELOID LEUKEMIA
Aug 11, 2026, 17:16 PM -
COST-CONSEQUENCE AND BUDGET IMPACT OF PATIENT BLOOD MANAGEMENT IN TWO CHINESE HOSPITALS
Aug 11, 2026, 17:16 PM -
PHYSICIAN DECISION LOGIC IN RURAL HEALTHCARE NETWORKS - A CROSS-SECTIONAL ANALYSIS OF REFERRAL AND ADMISSION PATTERNS
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF ONCE-WEEKLY ICOSEMA VERSUS INSULIN ICODEC AND INSULIN GLARGINE U100 FOR TREATING TYPE 2 DIABETES IN ITALY: LONG-TERM ANALYSES USING THE PRIME T2D MODEL BASED ON COMBINE 1 AND COMBINE 4
Aug 11, 2026, 17:16 PM -
QUALITATIVE CONTENT ANALYSIS OF RESPONSES TO THE NICE PUBLIC CONSULTATION ON EXA-CEL FOR THE TREATMENT OF PATIENTS WITH SEVERE SICKLE CELL DISEASE
Aug 11, 2026, 17:16 PM -
WHERE MUST THE HUMAN REMAIN IN THE LOOP? EVALUATING EXPERT-VALIDATION CHECKPOINTS IN AI-ASSISTED HTA EVIDENCE WORKFLOWS
Aug 11, 2026, 17:16 PM -
THE INCIDENCE, MORTALITY, AND SURVIVAL OF MALIGNANT HEPATOCELLULAR CARCINOMA IN THE UNITED STATES: A SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) 2000-2023 DATABASE ANALYSIS
Aug 11, 2026, 17:16 PM -
PROJECTING DISPARITIES IN THE CLINICAL AND ECONOMIC BURDEN OF COPD BY NEIGHBOURHOOD-LEVEL SOCIOECONOMIC DEPRIVATION IN THE UNITED STATES
Aug 11, 2026, 17:16 PM -
ECONOMIC POSITIONING OF SURGERY WITH ABSORBABLE STEROID-ELUTING SINUS IMPLANTS VERSUS DUPILUMAB IN SEVERE CRSWNP: AN ITALIAN NATIONAL HEALTH SERVICE PAYER PERSPECTIVE
Aug 11, 2026, 17:16 PM -
SOCIOECONOMIC BURDEN OF HER2-POSITIVE BREAST CANCER IN ALGERIA: A PREVALENCE-BASED COST-OF-ILLNESS ANALYSIS
Aug 11, 2026, 17:16 PM
